- Home
- BKE vs BEAM Comparison
BKE vs BEAM Comparison
Compare BKE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | BEAM |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BKE | BEAM |
|---|---|---|
| Price | $46.43 | $26.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $49.38 |
| AVG Volume (30 Days) | 342.7K | ★ 1.8M |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | 6.43 | ★ 82.31 |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $1,297,835,000.00 | $24,000.00 |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $3.97 | $14.48 |
| P/E Ratio | $26.47 | ★ N/A |
| Revenue Growth | 6.58 | ★ 33.33 |
| 52 Week Low | $39.44 | $20.23 |
| 52 Week High | $58.52 | $38.26 |
Technical Indicators
Market Signals| Indicator | BKE | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 55.45 |
| Support Level | $46.80 | $25.29 |
| Resistance Level | $47.53 | $28.87 |
| Average True Range (ATR) | 1.12 | 1.56 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 69.05 | 56.51 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.